| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fcb093a174d5182b5854b704cb09354 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 |
| filingDate |
2008-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6ccdcc23557e1c5d04629451145f8c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaddd93fc68d881bbf9812a30f7655f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3aa6698283ee678ae9a18b7a7b788dee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c1e8d1a38c2a56567388c85bffdd187
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75e6da4928e62b4dd647fa306336b021 |
| publicationDate |
2008-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008287490-A1 |
| titleOfInvention |
Bis-pyridino containing compounds for the use in the treatment of CNS pathologies |
| abstract |
N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9180191-B2 |
| priorityDate |
2003-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |